ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2787

Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program

Kevin Winthrop1, Stephen Lindsey2, Masayoshi Harigai3, John D. Bradley4, Lei Chen4, David L. Hyslop4, Maher Issa4, Atsushi Nishikawa5, Sarah Witt4, Christina L. Dickson4 and Maxime Dougados6, 1Oregon Health & Science University, Portland, OR, 2Ochsner Health Center, Baton Rouge, LA, 3Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Eli Lilly and Company, Indianapolis, IN, 5Lilly Japan K.K., Kobe, Japan, 6Rene Descartes University, Cochin Hospital, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Janus kinase (JAK), opportunistic infections, rheumatoid arthritis (RA) and tuberculosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Session Title: Rheumatoid Arthritis – Clinical Aspects IV: Medications and Risk

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor approved in the EU for the treatment (trt) of moderately to severely active rheumatoid arthritis (RA) in adults. Compared to the general population, RA patients (pts) have an increased rate of tuberculosis (TB) and other potential opportunistic infections (OI). This analysis evaluated reported potential OI in RA pts treated with bari across 8 completed studies (4 Phase [Ph] 3, 3 Ph2, 1 Ph1) and 1 ongoing long-term extension (LTE) study, with data up to September 1, 2016.

Methods: The All bari RA analysis set included pts exposed to any bari dose, with exposure up to 5.5 years (yrs) (Ph 1-3 and LTE studies); the comparison with placebo (PBO) was based on 6 studies (Ph 2-3) with bari 4 mg QD and PBO up to week (wk) 24 (PBO-bari 4 mg set); dose-response assessment was based on 4 studies (Ph 2-3) with bari 2 and 4 mg QD, including the LTE (bari 2mg-4mg-extended set); the methotrexate (MTX) and adalimumab (ADA) data were based on the individual studies RA-BEGIN and RA-BEAM, respectively, up to wk 52. Reported potential OI were identified using Lilly-defined preferred terms from the Infections and infestations system organ class of the Medical Dictionary for Regulatory Activities (MedDRA) and pre-specified pairings of infecting organism and infection site. Sponsor medical review of these events was conducted to identify potential OI.

Results: Forty-five events, including TB, were identified in the All bari RA set (Table). There were 10 reported cases of TB (incidence rate [IR]=0.15/100 pt-yrs [PY]); all occurred in TB-endemic regions and 6 were associated with extra-pulmonary involvement. Bari was associated with an increased risk of trt emergent herpes zoster (HZ) compared to PBO in the PBO-bari 4 mg set (PBO IR=1.0/100PY, bari IR=4.3/100PY). In the All bari RA set, 18 HZ cases had distribution beyond the primary or adjacent dermatomes (considered potential OI), with 194 additional cases (overall IR=3.2/100PY). There were no visceral cases; 4 were associated with facial palsy (3) or other motor nerve palsy (1) and 3 had ocular involvement. Single cases of cytomegalovirus and Epstein-Barr virus infection were reported. Fungal events of candidiasis involving the esophagus (6), lung (1), and soft tissue (1), Pneumocystis jirovecii pneumonia (3, all in Japan) and single cases of histoplasmosis, paracoccidioidomycosis, and cryptococcal lung infections, and aspergillosis skin infection were reported. Few events occurred in the randomized, controlled portion of the studies, or with active comparator trt (MTX: none; ADA: 1 TB). Progressive multifocal leukoencephalopathy was not seen in the bari RA program.

Conclusion: Trt with bari was associated with an increased risk of HZ. TB and other potential OI, including HZ with distribution of infection beyond the primary or adjacent dermatomes, were uncommon with bari trt.

 



Disclosure: K. Winthrop, Pfizer, UCB, Abbvie, Eli Lilly and Company, Amgen, BMS, 5,Pfizer, BMS, 2; S. Lindsey, Eli Lilly and Company, 8; M. Harigai, Eisai Ltd, Takeda Ltd, Teijin, 2,Eli Lilly and Company, BMS, Chugai, Janssen, 5; J. D. Bradley, Eli Lilly and Company, 1,Eli Lilly and Company, 3; L. Chen, Eli Lilly and Company, 1,Eli Lilly and Company, 3; D. L. Hyslop, Eli Lilly and Company, 1,Eli Lilly and Company, 3; M. Issa, Eli Lilly and Company, 1,Eli Lilly and Company, 3; A. Nishikawa, Eli Lilly and Company, 1,Eli Lilly and Company, 3; S. Witt, Eli Lilly and Company, 1,Eli Lilly and Company, 3; C. L. Dickson, Eli Lilly and Company, 1,Eli Lilly and Company, 3; M. Dougados, Abbvie, Pfizer, Eli Lilly and Company, Novartis, UCB, Merck, Roche, BMS, 2,Abbvie, Pfizer, Eli Lilly and Company, Novartis, UCB, Merck, Roche, BMS, 5.

To cite this abstract in AMA style:

Winthrop K, Lindsey S, Harigai M, Bradley JD, Chen L, Hyslop DL, Issa M, Nishikawa A, Witt S, Dickson CL, Dougados M. Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tuberculosis-potential-opportunistic-infections-and-other-infections-of-interest-in-patients-with-moderate-to-severe-rheumatoid-arthritis-in-the-baricitinib-program/. Accessed July 2, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tuberculosis-potential-opportunistic-infections-and-other-infections-of-interest-in-patients-with-moderate-to-severe-rheumatoid-arthritis-in-the-baricitinib-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies